Haleon Plc Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing by Haleon Plc, dated April 7, 2025, reports a transaction in own shares executed under the company's share buyback programme announced on March 28, 2025. Haleon is a global leader in consumer health with a portfolio spanning Oral Health, Pain Relief, Respiratory Health, Digestive Health, and Vitamins, Minerals and Supplements (VMS).
Key Financial Metrics and Transaction Details
The filing details a specific share repurchase transaction rather than providing comprehensive financial statements for a reporting period.
- Date of Purchase: April 4, 2025
- Shares Purchased: 821,144 ordinary shares
- Price Range: Lowest 384.00 pence; Highest 401.30 pence
- Volume Weighted Average Price: 390.84 pence
- Post-Transaction Share Capital: 9,034,845,270 ordinary shares of £0.01 each
- Treasury Shares Held: 4,080,205
- Voting Shares Outstanding: 9,030,765,065
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity metrics.
Material Changes
The primary material change is the reduction of outstanding voting shares by 821,144 following the cancellation of the repurchased shares. The number of treasury shares increased to 4,080,205.
Guidance, Outlook, and Risks
This announcement does not contain updated financial guidance, management commentary on future outlook, or new risk factors. It serves strictly as a regulatory disclosure of a share buyback execution in compliance with the Market Abuse Regulation (EU) No 596/2014 as applied in the UK.
Key Facts for Investor Verification
- Verify the total number of shares repurchased under the March 28, 2025 programme to date.
- Confirm the remaining authorization limit for the current buyback programme.
- Review the full trade breakdown available via the London Stock Exchange link provided in the filing.
- Check subsequent filings for any changes to the treasury share count or voting rights calculations.